- Quintiles Transnational Holdings (Q +0.2%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey.
- ReWalk Robotics (RWLK +1.6%) upgraded to Buy from Hold by Canaccord Genuity.
- Ilumina (ILMN) upgraded to Overweight from Equal-Weight by Morgan Stanley but price target lowered to $162 (21% downside risk) from $190. Current price: ~$205.
- Sarepta Therapeutics (SRPT +1.6%) upgraded to Buy from Hold with a $30 (12% upside) price target by Canaccord Genuity.
- Roche (OTCQX:RHHBY -1.4%) upgraded to Buy from Neutral with a CHF325 (18% upside) price target by UBS.
- Sarepta Therapeutics downgraded to Neutral from Buy by Bank of America; price target raised to $28 (5% upside) from $20.
- Bruker (BRKR -0.9%) downgraded to Neutral from Buy with a $22 (13% upside) price target by Mizuho Securities.
- Achillion Pharmaceuticals (ACHN -0.3%) downgraded to Market Perform from Outperform by JMP Securities; $24 price target removed.
- Intercept Pharmaceuticals (ICPT) downgraded to Neutral from Buy with a $315 (21% upside) price target by Bank of America.
- Healthways (HWAY -1%) downgraded to Hold from Buy by Stifel Nicolaus; $25 price target removed.
- AmerisourceBergen (ABC -0.4%) downgraded to Market Perform from Outperform with a $121 (7% upside) price target by Cowen & Co.